BioTrack Capital, OrbiMed, Creacion Ventures and Hankang Capital led a $50m Series B in Sirius Therapeutics.

BioTrack Capital, a venture capital firm, OrbiMed, a healthcare-focused investment firm, Creacion Ventures, a venture capital firm, and Hankang Capital, a venture capital firm, led a $50m Series B in Sirius Therapeutics, a biotechnology company. “The successful completion of our Series B2 financing is a strong endorsement of our progress to date and our strategy going forward. We are deeply grateful to our new and existing investors for their continued support. The funds from this round will further advance our clinical programs and expand our pipeline, to deliver “transformative siRNA therapeutics for patients with chronic diseases around the world,” Qunsheng Ji, Sirius Therapeutics CEO.